A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
a study on Lung Cancer Non-Small Cell Lung Cancer Stomach Cancer Gastroesophageal Junction Cancer Hodgkin's Lymphoma Lymphoma Diffuse Large B-Cell Lymphoma Non-Hodgkin Lymphoma T Cell Lymphoma Skin Cancer/Melanoma Head and Neck Squamous Cell Carcinoma Squamous Cell Carcinoma Bladder Cancer Ovarian Cancer Breast Cancer Triple-Negative Breast Cancer Cervical Cancer Carcinoma Head and Neck Cancer
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer, NSCLC, cHL, HNSCC, TNBC, DLBCL, PTCL-NOS, Seattle Genetics, Lymphoma, Carcinoma, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck, Stomach Neoplasms, Brentuximab Vedotin, SEA-TGT, sasanlimab
Lead Scientist at UCSF
- Bridget Keenan
I am a physician scientist who works in translational cancer research and medical oncology. My clinical practice is in the Cancer Immunotherapy Clinic, where I work with patients with solid organ cancers who are being treated on early phase immunotherapy trials. I also attend on the Oncology Consult inpatient service.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Seagen Inc.
- Phase 1 research study
- Study Type
- About 132 people participating
- Last Updated